{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:14:15Z","timestamp":1778152455741,"version":"3.51.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10637-z","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:40:54Z","timestamp":1778150454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel treatment strategies in cardiogenic shock: an update on ongoing clinical trials"],"prefix":"10.1007","volume":"31","author":[{"given":"Mireia","family":"Padilla-Lopez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Manicone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L. D.","family":"Holle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian A.","family":"Wenzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Kimmoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sionis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"10637_CR1","doi-asserted-by":"publisher","unstructured":"Thiele H, Hassager C (2026) Cardiogenic Shock. New England Journal of Medicine 394:62\u201377. https:\/\/doi.org\/10.1056\/NEJMra2312086","DOI":"10.1056\/NEJMra2312086"},{"key":"10637_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/eurheartj\/ehv051","volume":"36","author":"H Thiele","year":"2015","unstructured":"Thiele H, Ohman EM, Desch S et al (2015) Management of cardiogenic shock. Eur Heart J 36:1223\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehv051","journal-title":"Eur Heart J"},{"key":"10637_CR3","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/ejhf.1922","volume":"22","author":"O Chioncel","year":"2020","unstructured":"Chioncel O, Parissis J, Mebazaa A et al (2020) Epidemiology, pathophysiology and contemporary management of cardiogenic shock \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22:1315\u201341. https:\/\/doi.org\/10.1002\/ejhf.1922","journal-title":"Eur J Heart Fail"},{"key":"10637_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/CIRCULATIONAHA.123.064527","volume":"148","author":"R Waksman","year":"2023","unstructured":"Waksman R, Pahuja M, van Diepen S et al (2023) Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the ShockAcademic Research Consortium (SHARC). Circulation 148:1113\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064527","journal-title":"Circulation"},{"key":"10637_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jacc.2015.11.048","volume":"67","author":"RU Shah","year":"2016","unstructured":"Shah RU, de Lemos JA, Wang TY et al (2016) Post-hospital outcomes of patients with acute myocardial infarction with cardiogenic shock. J Am Coll Cardiol 67:739\u201347. https:\/\/doi.org\/10.1016\/j.jacc.2015.11.048","journal-title":"J Am Coll Cardiol"},{"key":"10637_CR6","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"key":"10637_CR7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"10637_CR8","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.297.15.joc70035","volume":"297","author":"JH Alexander","year":"2007","unstructured":"Alexander JH, Reynolds HR, Stebbins AL et al (2007) Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock. JAMA 297:1657\u20131666. https:\/\/doi.org\/10.1001\/jama.297.15.joc70035","journal-title":"JAMA"},{"key":"10637_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2213-2600(21)00439-2","volume":"10","author":"M Karakas","year":"2022","unstructured":"Karakas M, Akin I, Burdelski C et al (2022) Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. Lancet Respir Med 10:247\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(21)00439-2","journal-title":"Lancet Respir Med"},{"key":"10637_CR10","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","volume":"377","author":"H Thiele","year":"2017","unstructured":"Thiele H, Akin I, Sandri M et al (2017) PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 377:2419\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1710261","journal-title":"N Engl J Med"},{"key":"10637_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367","author":"H Thiele","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann F-J et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367:1287\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1208410","journal-title":"N Engl J Med"},{"key":"10637_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2204511","volume":"388","author":"MM Suverein","year":"2023","unstructured":"Suverein MM, Delnoij TSR, Lorusso R et al (2023) Early extracorporeal CPR for refractory out-of-hospital cardiac arrest. N Engl J Med 388:299\u2013309. https:\/\/doi.org\/10.1056\/NEJMoa2204511","journal-title":"N Engl J Med"},{"key":"10637_CR13","doi-asserted-by":"publisher","unstructured":"Kimmoun A, O\u2019Brien C, Blumer V et al Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop. Lancet Respir Med 2025. https:\/\/doi.org\/10.1016\/S2213-2600(25)00084-0","DOI":"10.1016\/S2213-2600(25)00084-0"},{"key":"10637_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ejhf.3531","volume":"27","author":"V Galusko","year":"2025","unstructured":"Galusko V, Wenzl FA, Vandenbriele C et al (2025) Current and novel biomarkers in cardiogenic shock. Eur J Heart Fail 27:1106\u201325. https:\/\/doi.org\/10.1002\/ejhf.3531","journal-title":"Eur J Heart Fail"},{"key":"10637_CR15","doi-asserted-by":"publisher","unstructured":"Jentzer JC, Wiley B, Bennett C, et al (2020) Temporal Trends and Clinical Outcomes Associated with Vasopressor and Inotrope Use in The Cardiac Intensive Care Unit. Shock 53:452\u20139. https:\/\/doi.org\/10.1097\/SHK.0000000000001390","DOI":"10.1097\/SHK.0000000000001390"},{"key":"10637_CR16","doi-asserted-by":"crossref","unstructured":"Berg DD, Bohula EA, van Diepen S, et al (2019) Epidemiology of Shock in Contemporary Cardiac Intensive Care Units. Circ Cardiovasc Qual Outcomes 12.","DOI":"10.1016\/S0735-1097(19)31274-4"},{"key":"10637_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijcard.2013.12.276","volume":"172","author":"FK Triposkiadis","year":"2014","unstructured":"Triposkiadis FK, Butler J, Karayannis G et al (2014) Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. Int J Cardiol 172:115\u201321. https:\/\/doi.org\/10.1016\/j.ijcard.2013.12.276","journal-title":"Int J Cardiol"},{"key":"10637_CR18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","volume":"41","author":"GM Felker","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response tomilrinone in decompensated heart failure. J Am Coll Cardiol 41:997\u20131003. https:\/\/doi.org\/10.1016\/S0735-1097(02)02968-6","journal-title":"J Am Coll Cardiol"},{"key":"10637_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","volume":"46","author":"WT Abraham","year":"2005","unstructured":"Abraham WT, Adams KF, Fonarow GC et al (2005) In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. J Am Coll Cardiol 46:57\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2005.03.051","journal-title":"J Am Coll Cardiol"},{"key":"10637_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMoa0907118","volume":"362","author":"D De Backer","year":"2010","unstructured":"De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779\u201389. https:\/\/doi.org\/10.1056\/NEJMoa0907118","journal-title":"N Engl J Med"},{"key":"10637_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","volume":"72","author":"B Levy","year":"2018","unstructured":"Levy B, Clere-Jehl R, Legras A et al (2018) Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 72:173\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.051","journal-title":"J Am Coll Cardiol"},{"key":"10637_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1056\/NEJMoa2026845","volume":"385","author":"R Mathew","year":"2021","unstructured":"Mathew R, Di Santo P, Jung RG et al (2021) Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med 385:516\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2026845","journal-title":"N Engl J Med"},{"key":"10637_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00134-018-5222-9","volume":"44","author":"V L\u00e9opold","year":"2018","unstructured":"L\u00e9opold V, Gayat E, Pirracchio R et al (2018) Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med 44:847\u201356. https:\/\/doi.org\/10.1007\/s00134-018-5222-9","journal-title":"Intensive Care Med"},{"issue":"23","key":"10637_CR24","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1001\/jama.2013.282190","volume":"310","author":"HH Chen","year":"2013","unstructured":"Chen HH, Anstrom KJ, Givertz MM et al (2013) Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction. JAMA 310:2533. https:\/\/doi.org\/10.1001\/jama.2013.282190","journal-title":"JAMA"},{"key":"10637_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2022.01.018","volume":"79","author":"SS Naidu","year":"2022","unstructured":"Naidu SS, Baran DA, Jentzer JC et al (2022) SCAI SHOCK stage classification expert consensus update: A review and incorporation of validation studies. J Am Coll Cardiol 79:933\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2022.01.018","journal-title":"J Am Coll Cardiol"},{"key":"10637_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/CCM.0b013e3181ffe0eb","volume":"39","author":"B Levy","year":"2011","unstructured":"Levy B, Perez P, Perny J et al (2011) Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 39:450\u20135. https:\/\/doi.org\/10.1097\/CCM.0b013e3181ffe0eb","journal-title":"Crit Care Med"},{"key":"10637_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08573-0","volume":"25","author":"JB Kunkel","year":"2024","unstructured":"Kunkel JB, Holle SLD, Hassager C et al (2024) Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial. Trials 25:739. https:\/\/doi.org\/10.1186\/s13063-024-08573-0","journal-title":"Trials"},{"key":"10637_CR28","doi-asserted-by":"publisher","unstructured":"Obling L, Frydland M, Hansen R, et al (2018) Risk factors of late cardiogenic shock and mortality in ST-segment elevation myocardial infarction patients. Eur Heart J Acute Cardiovasc Care 7:7\u201315.https:\/\/doi.org\/10.1177\/2048872617706503","DOI":"10.1177\/2048872617706503"},{"key":"10637_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08567-y","volume":"25","author":"SLD Holle","year":"2024","unstructured":"Holle SLD, Kunkel JB, Hassager C et al (2024) Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial. Trials 25:731. https:\/\/doi.org\/10.1186\/s13063-024-08567-y","journal-title":"Trials"},{"key":"10637_CR30","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/eurjpc\/zwaa013","volume":"29","author":"S Montero","year":"2022","unstructured":"Montero S, Bayes-Genis A (2022) The overlooked tsunami of systemic inflammation in post-myocardial infarction cardiogenic shock. Eur J Prev Cardiol 29:2052\u20132054. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa013","journal-title":"Eur J Prev Cardiol"},{"key":"10637_CR31","doi-asserted-by":"publisher","unstructured":"Auffret V, Cottin Y, Leurent G, et al (2018) Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score. Eur Heart J 39:2090\u2013102. https:\/\/doi.org\/10.1093\/eurheartj\/ehy12","DOI":"10.1093\/eurheartj\/ehy12"},{"key":"10637_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/ehjacc\/zuad018","volume":"12","author":"JB Kunkel","year":"2023","unstructured":"Kunkel JB, Josiassen J, Helgestad OKL et al (2023) Inflammatory response by 48 h after admission and mortality in patients with acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care 12:306\u201314. https:\/\/doi.org\/10.1093\/ehjacc\/zuad018","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10637_CR33","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","volume":"37","author":"O Kleveland","year":"2016","unstructured":"Kleveland O, Kunszt G, Bratlie M et al (2016) Effect of a single dose of the Interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J 37:2406\u201313. https:\/\/doi.org\/10.1093\/eurheartj\/ehw171","journal-title":"Eur Heart J"},{"key":"10637_CR34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","volume":"77","author":"K Broch","year":"2021","unstructured":"Broch K, Anstensrud AK, Woxholt S et al (2021) Randomized trial of Interleukin-6 receptor inhibition in patients with acute ST-Segment elevation myocardial infarction. J Am Coll Cardiol 77:1845\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.049","journal-title":"J Am Coll Cardiol"},{"key":"10637_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1113\/jphysiol.2005.091801","volume":"569","author":"J Zhang","year":"2005","unstructured":"Zhang J, Lee MY, Cavalli M et al (2005) Sodium pump \u03b12 subunits control myogenic tone and blood pressure in mice. J Physiol 569:243\u201356. https:\/\/doi.org\/10.1113\/jphysiol.2005.091801","journal-title":"J Physiol"},{"key":"10637_CR36","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/ejhf.1843","volume":"22","author":"O Chioncel","year":"2020","unstructured":"Chioncel O, Collins SP, Butler J (2020) Istaroxime in acute heart failure: the holy grail is at HORIZON? Eur J Heart Fail 22:1694\u20131697. https:\/\/doi.org\/10.1002\/ejhf.1843","journal-title":"Eur J Heart Fail"},{"key":"10637_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ehf2.15102","volume":"12","author":"J Biegus","year":"2025","unstructured":"Biegus J, Mebazaa A, Metra M et al (2025) Safety and efficacy of up to 60 h of iv istaroxime in pre-cardiogenic shock patients: design of the SEISMiC trial. ESC Heart Fail 12:189\u201398. https:\/\/doi.org\/10.1002\/ehf2.15102","journal-title":"ESC Heart Fail"},{"key":"10637_CR38","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/ejhf.2629","volume":"24","author":"M Metra","year":"2022","unstructured":"Metra M, Chioncel O, Cotter G et al (2022) Safety and efficacy of istaroxime in patients with acute heart failure-related pre\u2010cardiogenic shock \u2013 a multicentre, randomized, double\u2010blind, placebo\u2010controlled, parallel group study (SEISMiC). Eur J Heart Fail 24:1967\u201377. https:\/\/doi.org\/10.1002\/ejhf.2629","journal-title":"Eur J Heart Fail"},{"key":"10637_CR39","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1093\/eurheartj\/sux001","volume":"19","author":"F Gustafsson","year":"2017","unstructured":"Gustafsson F, Guarracino F, Schwinger RHG (2017) The inodilator levosimendan as a treatment for acute heart failure in various settings. Eur Heart J Suppl 19:C2-7. https:\/\/doi.org\/10.1093\/eurheartj\/sux001","journal-title":"Eur Heart J Suppl"},{"key":"10637_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.medin.2017.08.009","volume":"42","author":"M Fang","year":"2018","unstructured":"Fang M, Cao H, Wang Z (2018) Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis. Med Intensiva 42:409\u2013415. https:\/\/doi.org\/10.1016\/j.medin.2017.08.009","journal-title":"Med Intensiva"},{"key":"10637_CR41","doi-asserted-by":"publisher","unstructured":"Combes A, Saura O, Nesseler N, et al (2026) Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock. JAMA 335:60. https:\/\/doi.org\/10.1001\/jama.2025.19843","DOI":"10.1001\/jama.2025.19843"},{"key":"10637_CR42","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","volume":"43","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski D, Kolesnik E, Tripolt NJ et al (2022) Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 43:4421\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehac494","journal-title":"Eur Heart J"},{"key":"10637_CR43","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR et al (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28:568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"10637_CR44","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V (2024) State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens 37:841\u2013852. https:\/\/doi.org\/10.1093\/ajh\/hpae092","journal-title":"Am J Hypertens"},{"key":"10637_CR45","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1161\/HYPERTENSIONAHA.123.21913","volume":"81","author":"A Picod","year":"2024","unstructured":"Picod A, Placier S, Genest M et al (2024) Circulating dipeptidyl peptidase 3 modulates systemic and renal hemodynamics through cleavage of Angiotensin peptides. Hypertension 81:927\u201335. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.21913","journal-title":"Hypertension"},{"key":"10637_CR46","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1111\/j.1742-4658.2011.08275.x","volume":"278","author":"SC Prajapati","year":"2011","unstructured":"Prajapati SC, Chauhan SS (2011) Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J 278:3256\u20133276. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08275.x","journal-title":"FEBS J"},{"key":"10637_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ejhf.1601","volume":"22","author":"B Deniau","year":"2020","unstructured":"Deniau B, Rehfeld L, Santos K et al (2020) Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur J Heart Fail 22:290\u20139. https:\/\/doi.org\/10.1002\/ejhf.1601","journal-title":"Eur J Heart Fail"},{"key":"10637_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13071350","volume":"13","author":"P Innelli","year":"2023","unstructured":"Innelli P, Lopizzo T, Patern\u00f2 G et al (2023) Dipeptidyl amino-peptidase 3 (DPP3) as an early marker of severity in a patient population with cardiogenic shock. Diagnostics Basel 13:1350. https:\/\/doi.org\/10.3390\/diagnostics13071350","journal-title":"Diagnostics Basel"},{"key":"10637_CR49","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehad545","volume":"44","author":"FA Wenzl","year":"2023","unstructured":"Wenzl FA, Bruno F, Kraler S et al (2023) Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes. Eur Heart J 44:3859\u201371. https:\/\/doi.org\/10.1093\/eurheartj\/ehad545","journal-title":"Eur Heart J"},{"key":"10637_CR50","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJMoa2307227","volume":"389","author":"H Thiele","year":"2023","unstructured":"Thiele H, Zeymer U, Akin I et al (2023) Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med 389:1286\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2307227","journal-title":"N Engl J Med"},{"key":"10637_CR51","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1161\/CIRCULATIONAHA.122.062949","volume":"147","author":"P Ostadal","year":"2023","unstructured":"Ostadal P, Rokyta R, Karasek J et al (2023) Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: Results of the ECMO-CS randomized clinical trial. Circulation 147:454\u201364. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062949","journal-title":"Circulation"},{"key":"10637_CR52","doi-asserted-by":"publisher","first-page":"482","DOI":"10.4244\/EIJ-D-23-00204","volume":"19","author":"AS Banning","year":"2023","unstructured":"Banning AS, Sabat\u00e9 M, Orban M et al (2023) Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial. EuroIntervention 19:482\u201392. https:\/\/doi.org\/10.4244\/EIJ-D-23-00204","journal-title":"EuroIntervention"},{"key":"10637_CR53","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","volume":"390","author":"JE M\u00f8ller","year":"2024","unstructured":"M\u00f8ller JE, Engstr\u00f8m T, Jensen LO et al (2024) Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med 390:1382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2312572","journal-title":"N Engl J Med"},{"key":"10637_CR54","doi-asserted-by":"publisher","unstructured":"Basir MB, Lemor A, Gorgis S et al (2023) Early Utilization of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock: The National Cardiogenic Shock Initiative. J Am Heart Assoc 12. https:\/\/doi.org\/10.1161\/JAHA.123.031401","DOI":"10.1161\/JAHA.123.031401"},{"key":"10637_CR55","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jchf.2018.09.009","volume":"6","author":"B Schrage","year":"2018","unstructured":"Schrage B, Burkhoff D, R\u00fcbsamen N et al (2018) Unloading of the left ventricle during venoarterial extracorporeal membrane oxygenation therapy in cardiogenic shock. JACC Heart Fail 6:1035\u201343. https:\/\/doi.org\/10.1016\/j.jchf.2018.09.009","journal-title":"JACC Heart Fail"},{"key":"10637_CR56","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.120.048792","volume":"142","author":"B Schrage","year":"2020","unstructured":"Schrage B, Becher PM, Bernhardt A et al (2020) Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation. Circulation 142:2095\u2013106. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.048792","journal-title":"Circulation"},{"key":"10637_CR57","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jacc.2018.10.085","volume":"73","author":"JJ Russo","year":"2019","unstructured":"Russo JJ, Aleksova N, Pitcher I et al (2019) Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol 73:654\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2018.10.085","journal-title":"J Am Coll Cardiol"},{"key":"10637_CR58","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.123.066179","volume":"148","author":"MC Kim","year":"2023","unstructured":"Kim MC, Lim Y, Lee SH et al (2023) Early left ventricular unloading or conventional approach after venoarterial extracorporeal membrane oxygenation: The EARLY-UNLOAD randomized clinical trial. Circulation 148:1570\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066179","journal-title":"Circulation"},{"key":"10637_CR59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.13.1664","volume":"294","author":"MR Shah","year":"2005","unstructured":"Shah MR, Hasselblad V, Stevenson LW et al (2005) Impact of the pulmonary artery catheter in critically ill patients. JAMA 294:1664. https:\/\/doi.org\/10.1001\/jama.294.13.1664","journal-title":"JAMA"},{"key":"10637_CR60","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1001\/JAMA.294.13.1625","volume":"294","author":"C Binanay","year":"2005","unstructured":"Binanay C, Califf R, Hasselblad V et al (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294:1625\u20131633. https:\/\/doi.org\/10.1001\/JAMA.294.13.1625","journal-title":"JAMA"},{"key":"10637_CR61","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.20.2713","volume":"290","author":"C Richard","year":"2003","unstructured":"Richard C, Warszawski J, Anguel N (2003) Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 290:2713. https:\/\/doi.org\/10.1001\/jama.290.20.2713","journal-title":"JAMA"},{"key":"10637_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ccd.28329","volume":"94","author":"DA Baran","year":"2019","unstructured":"Baran DA, Grines CL, Bailey S et al (2019) SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheter Cardiovasc Interv 94:29\u201337. https:\/\/doi.org\/10.1002\/ccd.28329","journal-title":"Catheter Cardiovasc Interv"},{"key":"10637_CR63","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.cardfail.2019.03.004","volume":"25","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Lemor A, Blumer V et al (2019) Trends in utilization and outcomes of pulmonary artery catheterization in heart failure with and without cardiogenic shock. J Card Fail 25:364\u201371. https:\/\/doi.org\/10.1016\/j.cardfail.2019.03.004","journal-title":"J Card Fail"},{"key":"10637_CR64","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1161\/CIRCULATIONAHA.119.043080","volume":"141","author":"A Saxena","year":"2020","unstructured":"Saxena A, Garan AR, Kapur NK et al (2020) Value of hemodynamic monitoring in patients with cardiogenic shock undergoing mechanical circulatory support. Circulation 141:1184\u201397. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.043080","journal-title":"Circulation"},{"key":"10637_CR65","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jchf.2020.08.012","volume":"8","author":"AR Garan","year":"2020","unstructured":"Garan AR, Kanwar M, Thayer KL et al (2020) Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in-hospital mortality. JACC Heart Fail 8:903\u201313. https:\/\/doi.org\/10.1016\/j.jchf.2020.08.012","journal-title":"JACC Heart Fail"},{"key":"10637_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ahj.2018.03.024","volume":"202","author":"WW O\u2019Neill","year":"2018","unstructured":"O\u2019Neill WW, Grines C, Schreiber T et al (2018) Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. Am Heart J 202:33\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2018.03.024","journal-title":"Am Heart J"},{"key":"10637_CR67","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cardfail.2023.05.001","volume":"29","author":"M Kanwar","year":"2023","unstructured":"Kanwar M, Blumer V, Zhang Y et al (2023) Pulmonary artery catheter use and risk of in-hospital death in heart failure cardiogenic shock. J Card Fail 29:1234\u201344. https:\/\/doi.org\/10.1016\/j.cardfail.2023.05.001","journal-title":"J Card Fail"},{"key":"10637_CR68","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1097\/CCM.0000000000004289","volume":"48","author":"S-M Cho","year":"2020","unstructured":"Cho S-M, Geocadin RG, Caturegli G et al (2020) Understanding characteristics of acute brain injury in adult extracorporeal membrane oxygenation: an autopsy study. Crit Care Med 48:e532-6. https:\/\/doi.org\/10.1097\/CCM.0000000000004289","journal-title":"Crit Care Med"},{"key":"10637_CR69","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1097\/CCM.0000000000003223","volume":"46","author":"R Sutter","year":"2018","unstructured":"Sutter R, Tisljar K, Marsch S (2018) Acute neurologic complications during extracorporeal membrane oxygenation: a systematic review. Crit Care Med 46:1506\u201313. https:\/\/doi.org\/10.1097\/CCM.0000000000003223","journal-title":"Crit Care Med"},{"key":"10637_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03533-5","volume":"25","author":"R Lorusso","year":"2021","unstructured":"Lorusso R, Belliato M, Mazzeffi M et al (2021) Neurological complications during veno-venous extracorporeal membrane oxygenation: Does the configuration matter? A retrospective analysis of the ELSO database. Crit Care 25:107. https:\/\/doi.org\/10.1186\/s13054-021-03533-5","journal-title":"Crit Care"},{"key":"10637_CR71","doi-asserted-by":"publisher","unstructured":"Kalra A, Kang JK, Khanduja S et al Long-Term Neuropsychiatric, Neurocognitive, and Functional Outcomes of Patients Receiving ECMO. Neurology 2024;102. https:\/\/doi.org\/10.1212\/WNL.0000000000208081","DOI":"10.1212\/WNL.0000000000208081"},{"key":"10637_CR72","doi-asserted-by":"publisher","unstructured":"Zhang LQ, Chang H, Kalra A et al Continuous Monitoring of Cerebral Autoregulation in Adults Supported by Extracorporeal Membrane Oxygenation. Res Sq 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-3300834\/v1","DOI":"10.21203\/rs.3.rs-3300834\/v1"},{"key":"10637_CR73","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s12028-020-01111-1","volume":"34","author":"N Joram","year":"2021","unstructured":"Joram N, Beqiri E, Pezzato S et al (2021) Continuous monitoring of cerebral autoregulation in children supported by extracorporeal membrane oxygenation: a pilot study. Neurocrit Care 34:935\u201345. https:\/\/doi.org\/10.1007\/s12028-020-01111-1","journal-title":"Neurocrit Care"},{"key":"10637_CR74","doi-asserted-by":"publisher","first-page":"H1118","DOI":"10.1152\/ajpheart.00267.2016","volume":"311","author":"P Toth","year":"2016","unstructured":"Toth P, Szarka N, Farkas E et al (2016) Traumatic brain injury-induced autoregulatory dysfunction and spreading depression-related neurovascular uncoupling: pathomechanisms, perspectives, and therapeutic implications. Am J Physiol Heart Circ Physiol 311:H1118-31. https:\/\/doi.org\/10.1152\/ajpheart.00267.2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10637_CR75","doi-asserted-by":"publisher","unstructured":"Hill CE, Blank LJ, Thibault D et al Continuous EEG is associated with favorable hospitalization outcomes for critically ill patients. Neurology 2019;92. https:\/\/doi.org\/10.1212\/WNL.0000000000006689","DOI":"10.1212\/WNL.0000000000006689"},{"key":"10637_CR76","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure. JAMA 297:1883. https:\/\/doi.org\/10.1001\/jama.297.17.1883","journal-title":"JAMA"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10637-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10637-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10637-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:40:58Z","timestamp":1778150458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10637-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10637"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10637-z","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ongoing clinical trials on cardiogenic shock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Central Illustration"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}